Jazz Pharmaceuticals 株価情報 (NASDAQ: JAZZ)

最新ニュース Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

HC Wainwright &amp; Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

News

Price Target

Reiteration

Analyst Ratings

JAZZ

HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $207 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $207 Price Target

On Wednesday, the FDA granted accelerated approval to Jazz Pharmaceuticals plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) <a href="https://www.benzinga.com/pressreleases/24/11/n42101689/jazz-pharmaceuticals-announces-u-s-fda-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-a" target="_blank" rel="noreferrer noopener">biliary tract cancer (BTC)</a>.
Ziihera&nbsp;was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41338366/jazz-pharmaceuticals-zepzelcatecentriq-combo-regimen-can-potentially-delay-disease-progression-ex" rel="noreferrer noopener">Jazz Pharmaceuticals&#8217; Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer</a>
The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC.
Regulatory reviews of zanidatamab for BTC remain ongoing in China and Europe.
In late 2022, Zymeworks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) entered into a license and collaboration agreement with Jazz Pharmaceuticals for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan, and all other territories except for those Asia Pacific territories previously <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42106981/fda-grants-u-s-approval-of-ziihera-zanidatamab-hrii-for-the-treatment-of-adults-with-previously-tr" rel="noreferrer noopener">licensed by Zymeworks</a>.
Under the Jazz license and collaboration agreement terms, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
Zymeworks says the approval represents the first FDA-approved therapy in its pipeline and validates the company&#8217;s Azymetric bispecific platform technology.
Price Action: JAZZ stock closed at $119.24 on Wednesday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42097813/eli-lilly-opts-to-develop-candidate-for-nervous-system-disease" target="_blank" rel="noreferrer noopener">Eli Lilly, Verge Genomics Opt To Develop ALS Drug Candidate</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

ZYME

FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $166 to $163.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $163

Jazz Pharmaceuticals and Zymeworks shares are trading higher after announcing their Zihera collaboration secured FDA approval to treat HER2-positive biliary tract cancer in adults.

Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of
<ul>
<li>Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S.</li>
<li>Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial</li>
<li>Company to host investor webcast on Dec. 11, 2024</li>
</ul>
In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland Limited (a subsidiary of Jazz Pharmaceuticals plc, collectively referred to as Jazz), for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. This collaboration allowed the Company to leverage Jazz's global commercial infrastructure, together with BeiGene's complementary strengths in certain Asia Pacific countries, to enable the global, rapid advancement of zanidatamab in multiple tumor types with the potential to provide a foundational HER2-targeted therapy for patients with difficult-to-treat cancers and limited treatment options. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25M based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500M in regulatory milestone payments and $862.5M in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.

Reported Earlier, Jazz Pharmaceuticals Secures FDA Approval For Ziihera (zanidatamab-hrii) To Treat HER2-Positive Biliary Tract Cancer In Adults

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $154 to $162.

Baird Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $162

Disclosed on November 13, Neena M Patil, EVP &amp; Chief Legal Officer at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: After conducting a thorough analysis, Patil sold 3,700 shares of Jazz Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558124000088//Archives/edgar/data/1232524/000176558124000088/0001765581-24-000088-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $456,617.
During Thursday's morning session, Jazz Pharmaceuticals shares down by 0.5%, currently priced at $127.01.
<h3>Get to Know Jazz Pharmaceuticals Better</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Economic Impact: An Analysis</h3>
Revenue Growth: Over the 3 months period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 8.52% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: Achieving a high gross margin of 89.42%, the company performs well in terms of cost management and profitability within its sector.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is significantly higher than the industry average. The company demonstrates a robust bottom-line performance with a current EPS of 3.5.
</li>
</ul>
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.49.
Understanding Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 18.08 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.18 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 8.65, Jazz Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Cracking Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Neena M Patil Executes Sell Order: Offloads $456K In Jazz Pharmaceuticals Stock

Six years after the United Kingdom legalized medical marijuana, families struggling to obtain life-saving medicine through the National Health Service (NHS) returned to Westminster on Tuesday, demanding change. They displayed photos of their loved ones who experienced significant improvement with medical marijuana, <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">reports</a> the Business of Cannabis.
<h2 class="wp-block-heading">NHS Is Failing Patients</h2>
Parents of children suffering from treatment-resistant epilepsy say their children have achieved seizure freedom with medical marijuana, thanks to cannabis' effectiveness compared as to conventional treatments.
Those gathered at Westminster criticizes the lack of NHS prescriptions, especially for children with epilepsy. Only about 50 children have access to private prescriptions due to the limited availability of pediatric neurologists willing to prescribe. Campaigners argued that the NHS is failing patients and called for a change.
"When prescription cannabis was legalized six years ago, this was not the situation that patients were promised or expected," said co-chairs of the Cannabis Industry Council, Dr Callie Seaman and Jamie Bartley. "It's time for the NHS to take action to expand public funding of cannabis medicines. A clear pathway should be established for patients to access prescriptions via the NHS, while private prescriptions could also be reimbursed by the public purse."
A Department of Health and Social Care spokesperson said: "Licensed cannabis-based medicines are routinely funded by the NHS where there is clear evidence of their quality, safety, and effectiveness. The NHS is taking an evidence-based approach to unlicensed cannabis-based treatments to ensure they are proved safe and effective before they can be considered for roll out more widely."
The need for cannabis as medicine in the U.K. was first highlighted by two cases involving children with severe epilepsy: <a href="https://www.benzinga.com/markets/cannabis/22/12/30175937/only-cannabis-stops-harrys-constant-seizures-says-mom-he-gets-it-for-free-thanks-to-i-am-billy-c">Billy Caldwell</a> and Alfie Dingley who were both using cannabis low-dose THC oil to treat their seizures.
While it is possible to access medical marijuana through the NHS, this rarely occurs and only in severe cases of epilepsy, chemotherapy-induced nausea or certain cases of muscle stiffness associated with MS. Since medical marijuana is not widely available through the NHS, many families struggle to <a href="https://www.benzinga.com/markets/cannabis/23/10/35388605/europes-high-uk-parents-need-nhs-help-for-daughters-seizures-thc-mmj-flowers-in-switzerland-more" target="_blank" rel="noreferrer noopener">afford life-saving medicine</a> for their children.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41492967/medical-marijuana-for-chronic-pain-could-cut-uks-national-health-costs-by-5-19b-annually-improvi">Medical Marijuana For Chronic Pain Could Cut UK&#8217;s National Health Costs By $5.19B Annually, Improving Health Outcomes</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
Per a report, new figures show the lack of prescribing of both unlicensed and licensed medical marijuana medicines, such as <a href="https://www.benzinga.com/topic/epidiolex">Epidiolex</a> and Sativex in the NHS. According to the NHS Business Service Authority, ‘fewer than five' patients have an NHS prescription for unlicensed cannabis medicines, while the <a href="https://www.benzinga.com/markets/cannabis/24/10/41431474/as-uk-medical-marijuana-market-booms-cannabis-clinics-receive-good-practice-guide">private sectors booms</a> with more than 35,000 medical cannabis patients.
Epidiolex is the only FDA-approved prescription CBD treatment for severe forms of epilepsy. It was developed and produced by GW Pharmaceuticals, which was <a href="https://www.benzinga.com/general/biotech/21/05/20989747/jazz-pharmaceuticals-closes-on-acquisition-of-gw-pharma-adds-cbd-drug-epidiolex-to-portfolio" target="_blank" rel="noreferrer noopener">acquired by</a> Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) in 2021. Epidiolex was first approved for treating seizures connected to Lennox-Gastaut syndrome and Dravet syndrome. In 2022, Epidiolex was approved <a href="https://www.benzinga.com/markets/cannabis/20/08/16902941/fda-approves-cbd-meds-from-gw-pharmaceuticals-to-treat-seizures" target="_blank" rel="noreferrer noopener">for treating seizures related to tuberous sclerosis complex</a>.
A Freedom of Information request reveals that no NHS trusts have prescribed cannabis flower, and only 27% prescribe licensed medical marijuana medicines, such as Epidiolex.
Continue reading on <a href="https://businessofcannabis.com/parents-of-children-with-epilepsy-demand-urgent-nhs-reform-for-cannabis-access/">Business of Cannabis</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/06/32693057/uk-moms-concern-as-no-doctor-will-prescribe-cannabis-for-her-daughters-300-daily-seizures">UK Mom&#8217;s Concern As No Doctor Will Prescribe Cannabis For Her Daughter&#8217;s 300 Daily Seizures</a></li>
</ul>
Photo: Benzinga edit of images by Marcin Nowak and Kimzy Nanney on Unsplash

Cannabis

Eurozone

UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy

TD Cowen maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and lowers the price target from $200 to $195.

TD Cowen Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $195

WIIM

Jazz Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results. Needham reiterated a Buy rating on the stock.

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported record third-quarter revenue of $1.05 billion on Wednesday afternoon, up 14% year-over-year, propelled by strong sales of key therapies like Xywav, Epidiolex and Rylaze.
The gross margin held steady at 89%. CEO Bruce Cozadd said Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Net Income Boosted By Adjusted Expenses</h3>
The company generated net income in the range of $430 to $550 million, increasing its GAAP EPS guidance to between $6.70 and $8.50. Jazz also adjusted its R&amp;D expense forecast, reflecting strategic prioritization within its pipeline, notably the anticipated fourth-quarter launch of zanidatamab for 2L BTC, a significant step in oncology.
<h3 class="wp-block-heading">Liquidity And Debt Management</h3>
With $2.6 billion in cash and investments, Jazz maintains $500 million in undrawn credit. Jazz repaid $575 million in senior notes due 2024, illustrating its disciplined debt management. The company <a href="https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-third-quarter-2024-financial-results-302297961.html">reported</a> that its financial and product strategies are expected to drive growth in critical therapeutic areas, enhancing long-term shareholder value.
Price Action: Jazz Pharmaceuticals shares remained relatively stable, closing at $111.55 with a slight gain of 0.11%
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/11/41774692/aurora-cannabis-reports-strong-q2-growth-driven-by-international-medical-marijuana-sales"> Aurora Cannabis Reports Strong Q2 Growth Driven By International Medical Marijuana Sales</a>

Earnings

Markets

Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth?

Guidance

Jazz Pharmaceuticals Sees FY24 Adj EPS $19.50-$20.60 Vs $19.59 Est.

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported quarterly earnings of $6.61 per share which beat the analyst consensus estimate of $5.50 by 20.18 percent. The company reported quarterly sales of $1.05 billion which beat the analyst consensus estimate of $1.04 billion by 1.76 percent. This is a 8.52 percent increase over sales of $972.14 million the same period last year.

Earnings Beats

Jazz Pharmaceuticals Q3 2024 Adj EPS $6.61 Beats $5.50 Estimate, Sales $1.05B Beat $1.04B Estimate

Bruce C Cozadd, Chairman &amp; CEO at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), disclosed an insider sell on November 5, according to a recent SEC filing.
What Happened: Cozadd's decision to sell 1,000 shares of Jazz Pharmaceuticals was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558124000086//Archives/edgar/data/1232524/000176558124000086/0001765581-24-000086-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $110,840.
In the Wednesday's morning session, Jazz Pharmaceuticals's shares are currently trading at $108.82, experiencing a down of 0.54%.
<h3>Get to Know Jazz Pharmaceuticals Better</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Economic Impact: An Analysis</h3>
Positive Revenue Trend: Examining Jazz Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.95% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 89.27%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is below the industry average, signaling challenges in bottom-line performance with a current EPS of 2.68.
</li>
</ul>
Debt Management: With a below-average debt-to-equity ratio of 1.54, Jazz Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 18.89 is lower than the industry average, implying a discounted valuation for Jazz Pharmaceuticals's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.0 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 8.8, Jazz Pharmaceuticals's EV/EBITDA ratio reflects a below-par valuation compared to industry averages signalling undervaluation
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Bruce C Cozadd Offloads $110K Worth Of Jazz Pharmaceuticals Stock

First presentation of top-line efficacy and safety results from the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial of adults with narcolepsy or idiopathic hypersomnia
For U.S. media and investors only
DUBLIN, Oct. 31, 2024 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that eight abstracts presenting data from across its sleep portfolio were featured at the 37th annual Psych Congress, held in Boston from October 29 through November 2, 2024. The data includes the top-line results of the Phase 4 DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) trial, evaluating the effectiveness of low-sodium oxybate on key sleep outcomes in adults with narcolepsy or idiopathic hypersomnia (IH). Notably, these DUET data are the first to show prospective improvements on excessive daytime sleepiness (EDS), as well as key polysomnography (PSG) outcomes of sleep disruption, among adults with narcolepsy treated with Xywav&#xAE; (calcium, magnesium, potassium, and sodium oxybates) oral solution. Further, new DUET data evaluating nighttime Xywav treatment in adults with IH demonstrate clinical improvements on daytime symptoms, including sleep inertia measured by the Patient Global Impression of Change (PGIc).&nbsp;
The DUET trial is a Phase 4, prospective, single-arm, open-label study to assess the effect of Xywav treatment on EDS, polysomnography parameters, and functional outcomes in adults with narcolepsy or IH. Observed adverse events were consistent with the known safety profile of Xywav, with the most common including nausea, dizziness and headache.

Jazz Pharmaceuticals Presents New Data At Psych Congress 2024 Confirming Xywav Oral Solution Treatment Benefits In Narcolepsy And Idiopathic Hypersomnia

With this ruling, the approval of LUMRYZ is upheld based on the FDA's determination that LUMRYZ is clinically superior to Jazz's twice-nightly oxybate products.
"We are pleased with the Court's ruling in favor of the FDA's clinical superiority determination for LUMRYZ in conjunction with final approval for use in adults with narcolepsy," the company said.

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

Avadel Pharmaceuticals Says US District Court Ruled In Favor Of FDA In Suit Brought By Jazz Pharmaceuticals Under Administrative Procedure Act Regarding LUMRYZ Approval

Across the recent three months, 12 analysts have shared their insights on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $171.67, along with a high estimate of $205.00 and a low estimate of $120.00. Highlighting a 1.67% decrease, the current average has fallen from the previous average price target of $174.58. 
<img src="https://www.benzinga.com/files/images/story/2024/1729713693_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Jazz Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$179.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$175.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$174.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$205.00</td>
<td>$208.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Jazz Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Jazz Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Jazz Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Get to Know Jazz Pharmaceuticals Better</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.95%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin is impressive, surpassing industry averages. With a net margin of 16.46%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.52%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.49%, the company showcases effective utilization of assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.54.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and raises the price target from $175 to $179.

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Raises Price Target to $179

Zymeworks (ZYME) announced, with Jazz Pharmaceuticals (JAZZ), that the U.S. FDA has granted accelerated approval of Ziihera 50mg/mL for injection f...

Zymeworks, Jazz Pharmaceuticals announce FDA approval of Ziihera

Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera

Piper Sandler lowered the firm's price target on Jazz Pharmaceuticals (JAZZ) to $163 from $166 and keeps an Overweight rating on the shares. The fi...

Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler

In a report released today, Joseph Thome from TD Cowen maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price targe...

TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

Needham analyst Ami Fadia reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $207.00. Ami Fad...

Positive Outlook for Jazz Pharmaceuticals Following Ziihera Approval

The Food and Drug Administration granted accelerated approval to zanidatamab-hrii, or Ziihera from Jazz Pharmaceuticals (JAZZ), Inc., a bispecific ...

FDA grants accelerated approval to Jazz Pharmaceuticals' Ziihera

Oren Livnat, an analyst from H.C. Wainwright, reiterated the Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report). The associated price targ...

Jazz Pharmaceuticals: Promising Growth Potential with Robust Pipeline and Undervalued Market Position

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price targ...

Barclays Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky

Roche (RHHBY) announced the FDA approval of a label expansion into biliary tract cancer, or BTC, for the Pathway anti-HER2/neu Rabbit Monoclonal Pr...

Roche announces FDA approval of label expansion into biliary tract cancer

RHHBY

RHHVF

Offerings

Press Releases

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

ニュース

最新ニュース Jazz Pharmaceuticals (NASDAQ:JAZZ) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル